Sana Biotechnology Inc
SANA
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.09B
Close$
$-0.03
100.7% downside
Current Fair Value
100.7% downsideOvervalued by 100.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.09 Billion |
|---|---|
| Enterprise Value | $1.11 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.96 |
| Beta | 2.1 |
| Outstanding Shares | 295,667,000 |
Return
| Return on Equity | -137.04% |
|---|---|
| Return on Assets | -49.09% |
| Return on Invested Capital | -64.22% |
Valuation & Multiples
| P/E Ratio | -5.17 |
|---|---|
| PEG | 16.08 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.62 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.48 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4683▲ 2.79% |
|---|---|
| Total Calls | 493,900▲ 46.47% |
| Total Puts | 231,300▲ 55.76% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 67.40%▲ 8.12% |
|---|---|
| Total Invested | $830.28M▲ 75.60% |
| Investors Holding | 218▲ 12.00% |
ESG Score
No data
About Sana Biotechnology Inc
265 employeesSana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana shares a vision of repairing and controlling genes, replacing missing or damaged cells, and making its therapies broadly avai...